Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis

被引：0
|
作者：
Sorokina, Irina
Ganshina, Inna
Ibragimova, Tansuly
Bondareva, Irina
Zhukova, Lyudmila
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
empegfilgrastim; neutropenia; pCR; dose intensity; G-CSF; breast carcinoma; neoadjuvant therapy;
D O I：
10.1158/1538-7445.SABCS22-P3-07-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-23
引用
收藏
页数：2
相关论文
共 37 条
  • [1] Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+breast cancer.
    Zhukova, Lyudmila
    Ibragimova, Tansylu
    Ganshina, Inna
    Filonenko, Daria
    Sorokina, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
    Snegovoy, A.
    Kononenko, I. B.
    Sorokina, I.
    Kiseleva, P.
    Mironenko, O.
    Berezina, A.
    Prosianikova, O.
    ANNALS OF ONCOLOGY, 2024, 35 : S1097 - S1098
  • [3] DEFENDOR: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors-The final analysis
    Snegovoy, Anton
    Kononenko, Inessa
    Radyukova, Irina
    Orlova, Svetlana
    Starostina, Tatiyana
    Sultanbaev, Alexander Valerievich
    Dubovichenko, Daria
    Dergunov, Alexander
    Saydullaeva, Alexandra
    Repina, Nadezhda
    Gronskaya, Yulia
    Rossokha, Elena
    Sorokina, Irina
    Prosianikova, Oksana
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Defendor: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors-The primary analysis.
    Snegovoy, Anton
    Dergunov, Alexander
    Tatyanenko, Anna
    Yakuba, Darya
    Elkova, Viktoriya
    Shalina, Anna
    Komoza, Yulia
    Dmitrochenko, Marina
    Soroka, Svetlana
    Shegurova, Margarita
    Chapko, Yana
    Dmitriev, Vadim
    Timin, Vladimir
    Rossokha, Elena
    Gronskaya, Yulia
    Kononenko, Inessa
    Sorokina, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18788 - E18788
  • [5] Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required
    Lakhanpal, Roopa
    Stuart-Harris, Robin
    Chan, Arlene
    Kotasek, Dusan
    Beith, Jane
    Cuff, Katharine
    Bastick, Patricia
    Lee, Clara
    BREAST CANCER MANAGEMENT, 2013, 2 (05) : 367 - 374
  • [6] Docetaxel/cyclophosphamide (TC) chemotherapy for early breast cancer: is primary G-CSF prophylaxis necessary?
    Stanley, B.
    Macpherson, I.
    SCOTTISH MEDICAL JOURNAL, 2013, 58 (03) : E44 - E45
  • [7] Docetaxel/Cyclophosphamide (TC) Chemotherapy for Early Breast Cancer: Is Primary g-csf Prophylaxis Necessary?
    McIlroy, P.
    Lumsden, G.
    Haslett, K.
    Macpherson, I. R.
    CANCER RESEARCH, 2010, 70
  • [8] Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients
    Chan, Arlene
    McGregor, Scott
    Liang, Wenbin
    BREAST, 2014, 23 (05): : 676 - 682
  • [9] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis
    Tran Do
    Rohan Medhekar
    Raksha Bhat
    Hua Chen
    Polly Niravath
    Meghana V. Trivedi
    Breast Cancer Research and Treatment, 2015, 153 : 591 - 597
  • [10] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the adjuvant docetaxel and cyclophosphamide in patients with early-stage breast cancer: A meta-analysis.
    Tran Do
    Niravath, Polly Ann
    Trivedi, Meghana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1234